Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,721 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo comparator dosing Clear all
Completed Phase 2Phase 3 Interventional

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

NCT01741194
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AC-1204, Placebo
Drug
Lead sponsor
Cerecin
Industry
Eligibility
66 Years to 90 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

NCT01006122
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy
Interventions
Placebo, PF-03654746
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study in Participants With Moderate to Severe Psoriasis

NCT01474512
View directory record Official record
Conditions
Psoriasis
Interventions
80 mg Ixekizumab Dosing Regimens 1, 2, and 3, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Anaheim, California • Bakersfield, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Results available

Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)

NCT00560612
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Paroxetine, Placebo
Drug
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

NCT01297270
View directory record Official record
Conditions
Hepatitis C
Interventions
BI201335, PegIFN/RBV, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
78
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts

NCT02402595
View directory record Official record
Conditions
Healthy
Interventions
AVP-923, AVP-786, Itraconazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RO7795081, Semaglutide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 2 Interventional

Chemotherapy Toxicity Reduction Via Urea Cycle Support

NCT00223730
View directory record Official record
Conditions
Cancer
Interventions
Citrulline, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 25, 2026, 7:33 PM EDT
Active, not recruiting Early Phase 1 Interventional

Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction

NCT04676399
View directory record Official record
Conditions
Chronic Pain, Hypertension, Diuretics Drug Reactions, SCS
Interventions
Hydrochlorothiazide 12.5mg, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years to 79 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 2 Interventional Results available

Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)

NCT03473340
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction
Interventions
Pirfenidone Capsule, Placebo Capsule
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Oct 25, 2026, 7:33 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Bimekizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Birmingham, Alabama • Fremont, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions

NCT02262689
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK2256294, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Not applicable Interventional Results available

The Effect of Omalizumab on Responses to Cat Allergen Challenge

NCT00604786
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
omalizumab, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 25, 2026, 7:33 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease

NCT03992469
View directory record Official record
Conditions
Crohn's Disease
Interventions
EBFAHF-2, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 2 Interventional

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

NCT06102005
View directory record Official record
Conditions
Asthma
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
48
States / cities
Scottsdale, Arizona • Yuma, Arizona • Lancaster, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

NCT02401542
View directory record Official record
Conditions
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
Interventions
Vofatamab, Docetaxel, Placebo
Drug
Lead sponsor
Rainier Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Gilbert, Arizona • Goodyear, Arizona • Duarte, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

NCT00307437
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

NCT01085812
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
30
States / cities
Beverly Hills, California • Encino, California • Garden Grove, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

NCT02187003
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Rivipansel, Placebo
Drug · Other
Lead sponsor
Biossil Inc.
Industry
Eligibility
6 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
126
States / cities
Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

NCT03836001
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Serlopitant Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Stanford University
Other
Eligibility
13 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Results available

Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients

NCT01395823
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
ergocalciferol supplementation, placebo
Dietary Supplement · Other
Lead sponsor
Dialysis Clinic, Inc.
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
12
States / cities
Redding, California • Albany, Georgia • Shreveport, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.

NCT01232283
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Apremilast, Placebo, Topical or Phototherapy Therapy
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
19
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Bakersfield, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Results available

STP206 for the Prevention of Necrotizing Enterocolitis (NEC)

NCT01954017
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
STP206, Control
Biological · Other
Lead sponsor
Leadiant Biosciences, Inc.
Industry
Eligibility
1 Day to 4 Days
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
13
States / cities
Hartford, Connecticut • Sunrise, Florida • Augusta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 4 Interventional

Comparison of Absorption of Vitamin D in Cystic Fibrosis

NCT01880346
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Vitamin D Powder, Vitamin D Oil
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 59 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 25, 2026, 7:33 PM EDT